Jan 16, 2020: WuXi Biologics and Bayer jointly announced an acquisition agreement that WuXi Biologics Germany GmbH will take over the operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany, and purchase the related equipment, in combination with a long-term lease contract for the building.
Based on the manufacturing agreement to be negotiated, the plant would be operated by the WuXi Biologics and serve as a back-up site for final product manufacturing of Kovaltry™, an antihemophilic factor (recombinant).
The transaction is expected to be concluded in the coming months subject to the satisfaction of the customary closing conditions. Financial details were not disclosed. https://www.wuxibiologics.com/wuxi-biologics-bayer-enter-acquisition-agreement-drug-product-plant-germany/
